Related Experiment Videos
Methimazole-induced agranulocytosis in Japanese patients with Graves' disease
H Tamai1, Y Takaichi, T Morita
1Department of Psychosomatic Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Abstract:
We reviewed the records of approximately 7000 Japanese patients whose hyperthyroidism was treated with methimazole (MMI) alone. Four patients (Group I) developed agranulocytosis during a second course of MMI therapy and eight patients (Group II) during an initial course. Six patients (three in each group) received less than 30 mg MMI daily. Agranulocytosis occurred after more than 2 months of therapy (12 weeks-1 year) in five patients. Seven patients were less than 40 years of age. One patient displayed a gradual protracted development of agranulocytosis. These results indicate that agranulocytosis after MMI may occur irrespective of dose, age, duration of treatment, and with a second exposure.
Insights
Agranulocytosis, a serious side effect of methimazole (MMI) for hyperthyroidism, can occur regardless of MMI dose, patient age, or treatment duration, even upon re-exposure.
Area of Science:
- Endocrinology
- Pharmacology
- Hematology
Background:
- Hyperthyroidism is a common endocrine disorder.
- Methimazole (MMI) is a primary treatment for hyperthyroidism.
- Agranulocytosis is a rare but severe adverse effect of MMI therapy.
Purpose of the Study:
- To investigate the occurrence of agranulocytosis in Japanese patients treated with methimazole (MMI).
- To identify risk factors and characteristics of MMI-induced agranulocytosis.
Main Methods:
- Retrospective review of approximately 7000 Japanese patients treated with MMI for hyperthyroidism.
- Analysis of patient records to identify cases of agranulocytosis.
- Categorization of cases based on initial or second course of MMI therapy.
Main Results:
- Agranulocytosis occurred in 12 patients (4 during second course, 8 during initial course).
- Cases were observed irrespective of MMI dose (some <30 mg/day), age (<40 years), or treatment duration (>2 months).
- One patient showed a protracted development of agranulocytosis.
Conclusions:
- MMI-induced agranulocytosis can occur at any point during therapy, including after prolonged treatment or upon re-exposure.
- Risk factors such as dose, age, and duration of treatment may not be definitive predictors of MMI-induced agranulocytosis.
- Clinicians should remain vigilant for agranulocytosis even in patients on low-dose MMI or those previously treated.